Stocktoria
Schrodinger, Inc. SDGR
Schrodinger, Inc. (SDGR) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $255.9M at a -40.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.455 |
| Retained earnings / assets | -0.866 |
| EBIT / assets | -0.23 |
| Equity / liabilities | 1.005 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SDGR | Schrodinger, Inc. | 4/9 | -0.33 | — | +23.3% |
| ARVN | ARVINAS, INC. | 4/9 | -1.73 | — | -0.3% |
| RCUS | Arcus Biosciences, Inc. | — | -0.75 | — | -4.3% |
| KROS | Keros Therapeutics, Inc. | 6/9 | 11.55 | 2.5 | — |
| LGND | LIGAND PHARMACEUTICALS INC | 4/9 | 6.75 | 48.9 | +60.4% |
| HROW | HARROW, INC. | 6/9 | 1.29 | — | +36.4% |
| AKBA | Akebia Therapeutics, Inc. | 5/9 | -12.49 | — | +47.5% |
About Schrodinger, Inc.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
FAQ
Is SDGR financially healthy?
Schrodinger, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SDGR pay a dividend?
No, Schrodinger, Inc. does not currently pay a dividend.
How profitable is SDGR?
In FY2025, Schrodinger, Inc. had a net margin of -40.4% and a return on equity of -28.4%.
What is the analyst price target for SDGR?
The average Wall-Street price target for Schrodinger, Inc. is $20.88, about 12.1% above the recent price, from 8 analysts (consensus: strong buy).
Is SDGR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Schrodinger, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.